<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04976296</url>
  </required_header>
  <id_info>
    <org_study_id>NOTICE study</org_study_id>
    <nct_id>NCT04976296</nct_id>
  </id_info>
  <brief_title>MRD Monitoring in Lung Cancer After Resection</brief_title>
  <official_title>Dynamic Molecular Residual Disease Detection in Stage I-IIIA Non-Small Cell Lung Cancer After Radical Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Provincial People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The conception of molecular residual disease (MRD) extending from hematologic tumor to solid&#xD;
      tumors. Evidences supporting MRD evaluation for lung cancer by liquid biopsy has gradually&#xD;
      accumulated, especially circulating tumor DNA (ctDNA). In this observational study, the&#xD;
      investigators prospectively enroll stage I-IIIA non-small cell lung cancer (NSCLC) patients&#xD;
      who underwent complete resection. Preoperative blood sample, tumor tissue and dynamic&#xD;
      postoperative blood samples are collected continuously for MRD detection. This study aim to&#xD;
      explore the prognostic value of MRD for stage I-IIIA NSCLC patients after complete resection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There will be a rapid surge in research about molecular residual disease (MRD) for solid&#xD;
      cancer in the near future. However, MRD differed significantly between tumor types and&#xD;
      between contexts; there continues to be a considerable lack of awareness and knowledge about&#xD;
      using MRD in lung cancer. Hence, this study aims to investigate the value of MRD in NSCLC&#xD;
      patients who underwent complete resection. Preoperative blood sample (20ml), tumor tissue and&#xD;
      dynamic postoperative blood samples (20ml) are collected continuously for MRD detection. The&#xD;
      follow-up was performed once every 3 to 6 months. The primary objective of this study is to&#xD;
      assess the prognostic value of MRD for stage I-IIIA NSCLC patients after complete resection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The prognostic value of MRD</measure>
    <time_frame>5 year</time_frame>
    <description>The survival difference between MRD positive and MRD negative patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The predictive value of MRD</measure>
    <time_frame>5 year</time_frame>
    <description>The separative value adjuvant chemotherapy or target therapy in MRD positive population and MRD negative population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The lead time of MRD</measure>
    <time_frame>5 year</time_frame>
    <description>The median lead time of detectable MRD before regular imaging finding.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Stage I-IIIA NSCLC patients after complete resection</arm_group_label>
    <description>For stage I-IIIA NSCLC patients who underwent complete resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRD detection</intervention_name>
    <description>The Geneplus OncoMRD lung assay is used to detect the MRD status.</description>
    <arm_group_label>Stage I-IIIA NSCLC patients after complete resection</arm_group_label>
    <other_name>Geneplus OncoMRD lung assay</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma cell free DNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The pathological diagnosis confirmed stage I-IIIA NSCLC patients who underwent complete&#xD;
        resection. No history of other malignant tumors within 5 years.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of histologically confirmed NSCLC (WHO 2015 classification) with resectable&#xD;
             (stage I-IIIA) disease.&#xD;
&#xD;
          -  Complete resection&#xD;
&#xD;
          -  Age ≥18 years at the time of screening&#xD;
&#xD;
          -  Capable of giving signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Mixed small cell and NSCLC histology&#xD;
&#xD;
          -  Rx, R1 or R2 resection&#xD;
&#xD;
          -  History of other malignant tumors within 5 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xue-Ning Yang, Ph.D</last_name>
    <phone>020-83827812-51311</phone>
    <email>yangxuening@gdph.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jia-Tao Zhang, Ph.D</last_name>
    <phone>020-83827812-51311</phone>
    <email>Z18820792959@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangdong Lung Cancer Institute &amp; Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510030</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xue-Ning Yang, Ph.D</last_name>
      <phone>020-83827812-51311</phone>
      <email>yangxuening@gdph.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Jia-Tao Zhang, Ph.D</last_name>
      <phone>020-83827812-51311</phone>
      <email>Z18820792959@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat Rev Clin Oncol. 2019 Jul;16(7):409-424. doi: 10.1038/s41571-019-0187-3. Review.</citation>
    <PMID>30796368</PMID>
  </reference>
  <reference>
    <citation>Abbosh C, Birkbak NJ, Swanton C. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection. Nat Rev Clin Oncol. 2018 Sep;15(9):577-586. doi: 10.1038/s41571-018-0058-3. Review.</citation>
    <PMID>29968853</PMID>
  </reference>
  <reference>
    <citation>Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, Khodadoust MS, Esfahani MS, Liu CL, Zhou L, Scherer F, Kurtz DM, Say C, Carter JN, Merriott DJ, Dudley JC, Binkley MS, Modlin L, Padda SK, Gensheimer MF, West RB, Shrager JB, Neal JW, Wakelee HA, Loo BW Jr, Alizadeh AA, Diehn M. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discov. 2017 Dec;7(12):1394-1403. doi: 10.1158/2159-8290.CD-17-0716. Epub 2017 Sep 24.</citation>
    <PMID>28899864</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 19, 2021</study_first_submitted>
  <study_first_submitted_qc>July 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangdong Provincial People's Hospital</investigator_affiliation>
    <investigator_full_name>Xue-Ning Yang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Molecular residual disease</keyword>
  <keyword>Circulating tumor DNA</keyword>
  <keyword>Disease relapse</keyword>
  <keyword>Predictive value</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The IPD could be shared after seeking consent from the corresponding investigator.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

